Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
lyc-30937-ec (4 trials)
lyc-55716 (2 trials)
pembrolizumab (keytruda) (1 trial)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Colitis (Phase 2)
Colitis, Ulcerative (Phase 2)
Lung Neoplasms (Phase 1)
Neoplasm Metastasis (Phase 2)
Psoriasis (Phase 2)
Ulcer (Phase 2)
Trials (6 total)
Trial APIs (3 total)